The longevity industry is moving fast.
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, epitalon, and Semax — for addition to the 503A Bulk Drug Substances list, the roster of ingredients licensed compounding pharmacies may legally prepare against a prescription. A seventh compound under review, emideltide, was rejected.
Parts of the longevity community are celebrating this as a legitimization of compounds that have long operated in regulatory gray areas. The clinical reality is more complicated — and GLA members should understand exactly why.
What actually happened
The votes were narrow: 8–6 with one abstention for BPC-157, KPV, and TB-500; 7–5 for MOTS-c. Every recommendation came over the objection of the FDA’s own scientific staff, who had applied the agency’s standard four-factor review — chemical characterization, safety, evidence of effectiveness, and historical use — and concluded that none of the seven peptides under review belonged on the list.
What this vote is not: FDA approval. It is not evidence of clinical benefit. It is not a change in what is legal to prescribe or compound today. The regulatory pathway from committee recommendation to an actual, enforceable rule change requires formal notice-and-comment rulemaking — a process that realistically extends 8–12 months, into 2027. Until then, the legal status for prescribing purposes is unchanged.
What FDA’s own reviewers found
In its briefing package, agency staff concluded there was a lack of evidence to support BPC-157 as an effective treatment for ulcerative colitis. During the hearing, an FDA scientist raised a more fundamental question — “What is BPC-157?” — pointing out that products sold under that name have shown inconsistent chemical composition from manufacturer to manufacturer, meaning basic identity and quality standards haven’t been established.
One committee member who voted against the recommendation, Brian Lee of the Keck School of Medicine of USC, summarized the safety concern directly: the existing randomized data suggests BPC-157 may be no better than placebo, and because serious harms like liver injury are often missed in self-reported outcomes, a favorable committee vote risks being read as an endorsement the evidence doesn’t support.
Notably, even some members who voted yes acknowledged the evidence gap. Panel critics noted that several yes votes leaned on “medical freedom” and patient-access arguments rather than clinical evidence, with one yes-voting member describing himself as “frankly disappointed at how incomplete the data was.”
The distinction that matters
A compounding pathway is a regulatory mechanism, not a scientific verdict. Accessibility is not efficacy. A committee vote is not clinical evidence.
GLA’s clinical position is consistent with where the evidence actually stands: peptides with robust human randomized-trial support — insulin and GLP-1 receptor agonists among them — belong in a different evidence category than compounds whose primary support is biological plausibility, animal data, and market momentum. Most peptides currently marketed in the longevity space, including the six addressed in this vote, are not yet in that category. Biological plausibility, anecdote, and commercial enthusiasm are not substitutes for randomized controlled trials demonstrating meaningful clinical benefit in humans.
What this means for practice: the vote is not a green light to prescribe or recommend these compounds as evidence-based longevity interventions. The scientific standard has not changed. Treat this vote as a regulatory signal worth watching — not as clinical validation.
As the rulemaking process unfolds over the coming months, GLA will continue tracking it and providing members with the science-grounded context to navigate it professionally.
For members who want the most technically detailed account of the committee’s deliberations, RAPS’ coverage of the July 23–24 PCAC meeting is the most precise summary of the evidence gaps FDA scientists identified.
Sources cited in this article:
- FDA Pharmacy Compounding Advisory Committee — official meeting record, July 23–24, 2026
- RAPS — “FDA advisory committee backs two controversial peptides”
- STAT News — “In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides”
- The Hill — “FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists”